bone void filler News
-
Graftys Achieves Ce Recertification And Mdsap Certification For Australia, Brazil, Canada And Usa
GRAFTYS SA (“Graftys”), a global leader in resorbable bone cements, is pleased to announce the CE recertification in Europe and the certification of its Quality Management System in conformity with the Medical Device Single Audit Program (MDSAP) in Australia, Brazil, Canada and the United States of America for the Design, Manufacture and Distribution of its Sterile Calcium Phosphate ...
By Graftys
-
Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft
Schlieren (Zurich), Switzerland, April 27, 2022 – Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today provided a first-quarter business update, showing a significant acceleration in product sales of its Medical devices segment. Medical devices sales increased 102% in Q1 2022 compared to Q1 2021. The U.S. Food and Drug Administration (FDA) cleared ...
-
Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft
Schlieren (Zurich), Switzerland, April 27, 2022 – Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today provided a first-quarter business update, showing a significant acceleration in product sales of its Medical devices segment. Medical devices sales increased 102% in Q1 2022 compared to Q1 2021. The U.S. Food and Drug Administration (FDA) cleared ...
-
Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft
Schlieren (Zurich), Switzerland, April 27, 2022 – Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today provided a first-quarter business update, showing a significant acceleration in product sales of its Medical devices segment. Medical devices sales increased 102% in Q1 2022 compared to Q1 2021. The U.S. Food and Drug Administration (FDA) cleared ...
-
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences’s MagnetOs Flex Matrix Cleared by FDA for Spinal Indications
Schlieren (Zurich), Switzerland, April 21, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs Flex Matrix has been cleared by the U.S. Food and Drug Administration (FDA) as a bone void filler for use in the posterolateral spine. MagnetOs Flex Matrix is a new open matrix bone ...
-
Bonesupport Awarded Synthetic Implantable Products Agreement With Premier
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, has been awarded a group purchasing agreement for Synthetic Implantable Products with Premier. Effective July 1st, the new agreement allows Premier members, at their discretion, to take advantage of pricing and terms pre-negotiated by Premier for CERAMENT® BONE VOID FILLER. “The awarded ...
-
NuShores BioSciences attracts medical devices manufacturing professional to Little Rock
Mark Pelo will lead NuShores’ production of NuCress™ bone regenerative product line. Little Rock, AR – NuShores Biosciences LLC (NuShores), founded and based in Little Rock, Arkansas, announced today that Mr. Mark Pelo has accepted the position of Manufacturing Manager and will move to Little Rock from the Pittsburgh area. He will lead NuShores Generation 1 manufacturing of ...
-
Molecular Matrix, Inc. Forms Strategic Alliance with Philosys Healthcare
On August 7, 2019, Molecular Matrix, Inc. (MMI) announced the signing of a Memorandum of Understanding (MOU) with Philosys Healthcare Co., Ltd., a biomedical distribution and manufacturing company based in Seongnam, South Korea. MMI is a biotechnology company that began as a startup at UC Davis, and after more than 10 years of research and development has created a scaffold for bone tissue ...
-
NuShores Biosciences receives new contract for intelligent manufacturing automation of NuCress medical devices
Little Rock, AR – NuShores Biosciences LLC has won a 3-year, $2.8M contract from the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium associated with the U.S. Army Medical Research and Development Command. The contract will enable NuShores to develop intelligent automated production of its NuCress™ bone void filler scaffold products using ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you